Epilepsy Foundation
12
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.3%
1 terminated/withdrawn out of 12 trials
90.0%
+3.5% vs industry average
25%
3 trials in Phase 3/4
44%
4 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Registry and Natural History Study for Progressive Myoclonus Epilepsy Type 1 (EPM1)
Role: collaborator
Novel Helmet Design in Patients With Seizures
Role: collaborator
Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy
Role: collaborator
Low-Glycemic (LGI) Diet in Pregnant People With Epilepsy
Role: collaborator
Group Cognitive Behavioral Therapy to Treat Depression in an Epilepsy Clinic Setting
Role: collaborator
Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)
Role: collaborator
Efficacy of TDCS for Treating Working Memory Dysfunction and Depression in Temporal Lobe Epilepsy
Role: collaborator
Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?
Role: collaborator
Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design
Role: collaborator
Medication Adherence in Individuals With Epilepsy
Role: collaborator
Treatment Trial for Psychogenic Nonepileptic Seizures
Role: collaborator
External Trigeminal Nerve Stimulation for Epilepsy
Role: collaborator
All 12 trials loaded